Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy

Objective. Previous case series have examined the relationship between anti-jo-1 antibody levels and myositis disease activity, demonstrating equivocal results. Using enzyme-linked immunosorbent assays (ELISAs) and novel measures of myositis disease activity, the current study was undertaken to systematically reexamine the association between anti-Jo-1 antibody levels and various disease manifestations of myositis. Methods. Serum anti-jo-1 antibody levels were quantified using 2 independent ELISA methods, while disease activity was retrospectively graded using the Myositis Disease Activity Assessment Tool, which measures disease activity in 7 different organ systems via the Myositis Disease Activity Assessment Visual Analog Scale (VAS) and the Myositis Intention-to-Treat Index (MITAX) components. Spearman's rank correlation coefficients and mixed linear regression analysis were used to identify associations between anti-jo-1 antibody levels and organ-specific disease activity in crosssectional and longitudinal analyses, respectively. Results. Cross-sectional assessment of 81 patients with anti-Jo-1 antibody revealed a modest correlation between the anti-jo-1 antibody level and the serum creatine kinase (CK) level, as well as muscle and joint disease activity. Correlation coefficients were similar for CK levels (r(s) = 0.38, P = 0.002), myositis VAS (r(s) = 0.36, P = 0.002), and arthritis VAS (rs = 0.40, P = 0.001). In multiple regression analyses of 11 patients with serial samples, anti-jo-1 antibody levels correlated significantly with CK levels (R-2 = 0.65, P = 0.0002), myositis VAS (R-2 = 0.53, P = 0.0008), arthritis VAS (R2 = 0.53, P = 0.006), pulmonary VAS, = 0.69, P 0.005), global VAS (R-2 0.63, P = 0.002), and global MITAX (R-2 = 0.64, P 0.0003). Conclusion. In this large series of patients with idiopathic inflammatory myopathy, anti-jo-1 antibody levels correlated modestly with muscle and joint disease, an association confirmed by a custom ELISA using recombinant human Jo-1. More striking associations emerged in a smaller longitudinal subset of patients that link anti-jo-1 antibody levels to muscle, joint, lung, and global disease activity.